MAIN LICENSE AND REGISTRY CONTENTS INDEX CONTACT


MONOCLONAL ANTIBODY INDEX© -- 2012 update
Cancer and non-neoplasic diseases (in separate databases), including in both the
BIOMARKER INDEX©

________

VACCINE ANTIGEN INDEX© -- 2012 update
including the
ONCOLYTIC VIRUS INDEX©

Since 1992.

icon



Fully searchable biotechnology database e-books with information on more than 9000 monoclonal antibodies produced for the diagnosis and therapy of human cancer, AIDS, SARS and other infections, heart, vascular and coagulation diseases, transplantation, inflammation, Alzheimer's disease, autoimmunity and other pathologies or uses as well as for biomarker and proteomics research, indicating all available data on:

- Antibody name(s)
- Antibody species
- Antibody type
- Antibody characteristics
- Related antibodies
- Target tissue/cell type
- Target disease or use
- Antigen or biomarker name
- Antigen molecular weight
- Antigen characteristics
- Clinical study phase
- Patent assignee, producer, developer or distributor and their respective technical or commercial names for the antibody, antigen or derivatives.
- References of production, characteristics and use obtained from journals, patents, abstracts, press releases and reports available until January 2012.

More than 4900 antibodies for cancer, main and related, and more than 4800 for non-neoplasic diseases. Including anti-idiotypic, bispecific, human, humanized, chimeric, reshaped, deimmunized, multivalent, diabodies, single chain-Fv (scFv), minibodies, affibodies, peptabodies, fusion proteins, transgenic, Fab fragments, pseudo-antibodies, catalytic, aglycosylated, glycosylated, pegylated, immunotoxins, conjugates, trifunctional, immunoadhesins, piezoimmunosensors, mimobodies, single domain, nanobodies, vaccibodies, intrabodies, immunocytokines, triplebodies, hexavalent, aptamers, crossmabs, etc.

Information presented in an easy-to-screen table format with selected data on:

- Who are the leaders?: over 650 products in clinical study for imaging and therapy with 50 approvals (some withdrawed or suspended) and 74 in phase 3.

- What's up now?: new antibodies added in the latest edition .

- Which are the targets?: included in the BIOMARKER INDEX© annex with the characteristics of the main target antigens / epitopes / gene products / biomarkers (more than 1500 in vol. 1 and more than 1000 in vol. 2).

The VACCINE ANTIGEN INDEX© is a fully searchable database of cells, antigens, DNA plasmids, vectors, antibodies and adjuvants ranked by study phase as vaccines for cancer (589 products with 352 in clinical study, 12 approvals and 36 in phase 3) and for other non-neoplasic and emerging diseases (244 products with 118 in clinical study, 3 approvals and 6 in phase 3).

The ONCOLYTIC VIRUS INDEX© contains information on specific oncolytic viruses and cytolytic cell lines (177 products with 45 in clinical study, 1 approval and 3 in phase 3)

Three all-in-one, up-to-date reference databases (no additional modules to buy) and a great brainstorming tool that will show you the latest advances, give clues on future trends and save you a lot of time (and money) in bibliographic searches on monoclonal antibodies, a technology born in 1975 with a proven therapeutic and diagnostic utility and with worldwide sales of more than $48 billion in 2010 that are expected to reach nearly $125 billion by 2020.

Therapeutic vaccines reached $16 billion sales in 2007 and cancer vaccines are expected to increase sales from more than $1 billion in 2008 to $4.3 billion by 2019. The immunoassay market is expected to increase from $12 billion in 2005 to $23 billion in 2019.


LINKS:

NEW BIOMARKER DISCOVERY AND IDENTIFICATION SYSTEM.

ALGORIMUT©: MUTATION PREDICTION ALGORITHM.

TIME-LAPSE SEQUENTIAL QUANTITATIVE SINGLE-CELL PROTEOMIC ANALYSIS.

NEW DRUG-PROTEIN CONJUGATES.